Elicera Therapeutics AB. (10/5/20). "Press Release: Elicera Therapeutics Completes Oversubscribed Share Issue and Secures 13,2 MSEK in Financing".

	Organisation	Elicera Therapeutics AB
	Organisation 2	University of Uppsala (Uppsala University)
	Product	cancer immunotherapy (immuno-oncology, I-O)
	Product 2	venture capital
	Index term	Elicera Therapeutics–SEVERAL: investment, 202010 first financing round SEK13.2m share issue
	Person	El-Mosleh, Jamal (Elicera Therapeutics 202010– CEO before Immunicum AB 200709– CEO)

Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Read the press release in Swedish:
Download press release (pdf)
[ https://assets.website-files.com/5e85ca7e8347401d65425175/5f79c0da34c371e7c3b909b2_Pressmeddelande%20Elicera%20Therapeutics%20201005%20-%20Genomförd%20finansiering.pdf ]

Record changed: 2023-06-05